Changes in the expression of Glutathione S Transferase-π (GST-π) and P-glycoprotein (P-gp) in bronchoscopic specimen of patients with lung cancer before and after chemotherapy

G. Vlachogeorgos, E. Manali, C. Mermigkis, E. Blana, S. Legaki, N. Karagiannidis, V. Polychronopoulos (Athens, Greece)

Source: Annual Congress 2001 - Lung cancer biology
Session: Lung cancer biology
Session type: Thematic Poster Session
Number: 1597
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Vlachogeorgos, E. Manali, C. Mermigkis, E. Blana, S. Legaki, N. Karagiannidis, V. Polychronopoulos (Athens, Greece). Changes in the expression of Glutathione S Transferase-π (GST-π) and P-glycoprotein (P-gp) in bronchoscopic specimen of patients with lung cancer before and after chemotherapy. Eur Respir J 2001; 16: Suppl. 31, 1597

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
P-glycoprotein (p-gp) and lung resistance protein (lrp), as predictive factors of response to platinum-based chemotherapy for lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 231s
Year: 2001

The role of Pgp, MRP and LRP expression in chemotherapy response of small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 78s
Year: 2004

Is it possible to predict response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) on the basis of serum CYFRA 21-1 level (sCY21)?
Source: Eur Respir J 2002; 20: Suppl. 38, 74s
Year: 2002

Response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) according to their serum levels of chosen tumor markers (CYFRA 21-1 (CY21), CEA and NSE)
Source: Eur Respir J 2001; 18: Suppl. 33, 377s
Year: 2001

Induction chemotherapy (IC) followed by surgery (S) for advanced non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 463s
Year: 2002

Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC)
Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro
Year: 2020


Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC)
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012


Alvolar lymphocytes (AL) in patients with non-small cell lung cancer (NSCLC). Data from tumor-affected lobe
Source: International Congress 2015 – Connective tissue disorders
Year: 2015

24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016

Different efficacy between carboplatin (Cpl) and gemcitabine (Gem) on median survival time of elderly non small cell lung cancer (NSCLC) patients
Source: Eur Respir J 2005; 26: Suppl. 49, 77s
Year: 2005

LATE-BREAKING ABSTRACT: A mRNA signature predicts outcome of patients (pts) with advanced non small cell lung cancer (NSCLC) treated with cisplatin (C) and vinorelbine (V): A ELCWP prospective study
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012


Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo).
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018



Increased expression of WSX1 on alveolar lymphocytes (AL) in patients with early stage non-small cell lung cancer (NSCLC). Preliminary report
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014

Gemcitabine and cisplatin ( GD) as first line chemotherapy in patients with non-small-cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 464s
Year: 2002

Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010


Carbonic anhydrase 9 expression (CA9e) profile combined with growth patterns (GPs) in non-small cell lung cancer (NSCLC) identifies a group of patients with an extremely poor prognosis
Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology
Year: 2005


Polymorphism in GSTM1, GSTT1, p53 and CCR5 genes and lung cancer progression: relation to p53 and Ki-67 protein expression in tumors of non-small cell lung cancer patients
Source: Eur Respir J 2006; 28: Suppl. 50, 810s
Year: 2006

Heterogeneous reactivity of ICAM-1 on alveolar macrophages (AMs) in patients with non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 256s
Year: 2003

Expression of Fhit protein in non-small cell lung cancer (NSCLC) and its correlation with Ki-67, a proliferative marker
Source: Eur Respir J 2002; 20: Suppl. 38, 230s
Year: 2002

Relationship between a clinical drug resistance and immunohistochemical expression of P-glycoprotien, multidrug resistance protein, and p53 in small cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 231s
Year: 2002